FDA Issues CRL to Abeona for Potential RDEB Cell Therapy
Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.
Source: hcplive.com
Stay updated with breaking news from Pz Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.
This announcement is part of the overall evaluation period for the treatment, as the PDUFA target action date for pz-cel remains May 2024.